METASTATIC DEDIFFERENTIATED LIPOSARCOMA
Clinical trials for METASTATIC DEDIFFERENTIATED LIPOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC DEDIFFERENTIATED LIPOSARCOMA trials appear
Sign up with your email to follow new studies for METASTATIC DEDIFFERENTIATED LIPOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to shrink Hard-to-Treat sarcomas
Disease control OngoingThis study compares two treatments for advanced dedifferentiated liposarcoma, a rare cancer. One group gets palbociclib alone, the other gets palbociclib plus cemiplimab. The goal is to see if the combination helps stop cancer growth better than the single drug. About 77 adults w…
Matched conditions: METASTATIC DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New drug duo targets hard-to-treat sarcoma
Disease control OngoingThis study tests whether combining two drugs (etrumadenant and zimberelimab) can shrink tumors or slow the disease in people with advanced dedifferentiated liposarcoma that has returned, spread, or cannot be removed by surgery. About 16 adults with this rare soft-tissue cancer wi…
Matched conditions: METASTATIC DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New drug combo aims to fight rare cancers that Won't go away
Disease control OngoingThis study tests whether two immunotherapy drugs, oleclumab and durvalumab, can shrink or slow the growth of certain sarcomas (angiosarcoma, liposarcoma, and osteosarcoma) that have come back, spread, or stopped responding to standard treatment. About 75 adults and some teens (ag…
Matched conditions: METASTATIC DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:52 UTC